Infection and Antimicrobial Stewardship

Infection and antimicrobial stewardship is the area of critical care medicine concerned with recognizing, treating, and preventing infection in the critically ill while using antimicrobial agents responsibly. Intensive care units concentrate the most vulnerable patients, the heaviest device use, and the most intense antimicrobial exposure, which makes them both a focus of life-threatening infection and a principal driver of antimicrobial resistance.

Definition

Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents by promoting the optimal selection, dosing, route, and duration of therapy; in critical care it operates alongside infection prevention and the urgent treatment of suspected infection.

Scope

This area orients the reader to four linked themes: hospital-acquired infections that arise during ICU care, the choice of empiric antimicrobial therapy before a pathogen is identified, invasive fungal infections in critically ill hosts, and bacterial meningitis as a time-critical central-nervous-system infection. It frames how infection is detected, how treatment is initiated under uncertainty, and how stewardship balances the competing pressures of timely effective therapy and resistance containment. It is a reference overview and not clinical guidance.

Sub-topics

• Bacterial Meningitis
• Empiric Antimicrobial Therapy
• Invasive Fungal Infections in ICU
• Hospital-Acquired Infections (HAI) in ICU

Core questions

• How is infection distinguished from non-infectious inflammation in a critically ill patient?
• When pathogen and susceptibility are still unknown, how broad should initial empiric therapy be?
• How can early effective treatment be reconciled with restraint that protects against resistance?
• Which infections in the ICU are preventable, and through what mechanisms?

Key concepts

• Empiric versus targeted (definitive) therapy
• Time-to-effective-antimicrobial
• De-escalation and treatment duration
• Antimicrobial resistance and selection pressure
• Healthcare-associated and device-associated infection
• Source control
• Local antibiogram and ecology

Mechanisms

Critically ill patients lose normal barrier and immune defences and are exposed to invasive devices, creating portals for colonizing and nosocomial organisms. Effective antimicrobial therapy aims to suppress the pathogen quickly, and observational data link delay in effective therapy in septic shock to worse survival (Kumar 2006). At the same time, exposure to broad-spectrum agents selects for resistant organisms; the WHO priority pathogen framework underscores how resistance erodes the available drug armamentarium (Tacconelli 2018). Stewardship interventions seek the optimal point between these forces by guiding selection, narrowing once cultures return, and limiting unnecessary duration (Dellit 2007; Barlam 2016).

Clinical relevance

Infection is among the most common reasons for ICU admission and a leading cause of ICU mortality, and antimicrobial decisions made in critical care influence both individual outcomes and institution-wide resistance patterns. This entry describes how the field reasons about these trade-offs at a conceptual level; it is educational reference material and does not provide dosing, regimen selection, or individualized treatment advice.

Epidemiology

Sepsis and hospital-acquired infections account for a substantial share of critical-care morbidity and mortality worldwide, and the ICU is a recognized epicentre of multidrug-resistant organism emergence and transmission. The Surviving Sepsis Campaign guidelines synthesize the management framework for sepsis and septic shock that underlies much of ICU infection practice (Evans 2021).

History

Antimicrobial stewardship emerged as a formal discipline as resistance accelerated and broad-spectrum use expanded; the 2007 IDSA/SHEA institutional-program guidelines (Dellit 2007) and their 2016 implementation update (Barlam 2016) codified the structure of stewardship programs that now operate in most hospitals with intensive care units.

Debates

How fast and how broad should empiric therapy be in suspected sepsis?

Evidence linking delayed effective therapy to mortality pushes toward early broad coverage, while resistance concerns push toward restraint; reconciling speed with selectivity remains an active tension in critical-care infection practice.

Seminal works

• kumar-2006
• dellit-2007
• evans-2021

Frequently asked questions

What is the difference between empiric and targeted antimicrobial therapy?

Empiric therapy is started before the causative organism is known, based on the likely pathogens and local resistance patterns; targeted (definitive) therapy is the narrower regimen chosen once culture and susceptibility results identify the organism.

Why does stewardship matter in the ICU specifically?

Intensive care units combine the sickest patients, the most device exposure, and the heaviest broad-spectrum antimicrobial use, so they are both where rapid effective treatment most affects survival and where resistance is most strongly selected, making the stewardship trade-off most acute.